FDA Discussion Paper on Considerations for the Regulation of Generative AI-Enabled Medical Devices
On 18 August 2026, the U.S. Food and Drug Administration (FDA) issued a discussion paper seeking early stakeholder input on potential approaches to the regulation of generative artificial intelligence (GenAI)-enabled medical devices. Importantly, this is not a regulatory consultation on draft guidance or proposed policy. Rather, FDA is using the discussion paper to seek early stakeholder feedback and inform CDRH's ongoing consideration of regulatory approaches. FDA states that the paper is for discussion purposes only and does not propose or implement policy changes or communicate proposed or final regulatory expectations.
Overview
Authority | U.S. Food and Drug Administration (FDA) |
Date | 18 August 2026 |
Focus | Regulatory considerations for GenAI-enabled medical devices |
Type | Discussion paper and request for feedback |
Deadline for comments | 19 October 2026 |
What is this about?
FDA is seeking early input on how the distinctive characteristics of GenAI-enabled medical devices could be considered within a risk-based, total product life cycle approach.
The paper discusses challenges such as open-ended inputs, variable outputs, the ability to perform multiple subtasks, model changes and reliance on third-party foundation models. It explores possible approaches to risk assessment, premarket evaluation and postmarket monitoring, with attention to how risk may vary according to the activity performed by the device and the consequences of incorrect outputs.
FDA explicitly emphasizes the preliminary nature of the initiative. The approaches discussed are not intended to represent proposed regulatory expectations, including expectations for evidence in future marketing submissions. FDA also does not take a position in the paper on whether the approaches discussed fall within its existing legal authorities or would require new authorities.
Consultation details
Rather than consulting on a defined regulatory proposal, FDA poses discussion questions intended to inform its thinking and promote broader stakeholder dialogue. Key areas include:
Risk assessment: Possible approaches based on the activity performed by the device and the consequences of incorrect outputs
Premarket evaluation: Potential competency-based approaches including device benchmarking and clinical confirmation
Postmarket monitoring and modifications: Performance monitoring, re-benchmarking, change management and Predetermined Change Control Plans (PCCPs)
Other considerations: Third-party foundation models and agentic GenAI-enabled devices
Respondents may address only the questions relevant to their expertise or experience.
Key timeline
Deadline for comments: 19 October 2026
Why this matters
Although the paper does not establish or propose regulatory requirements, it provides insight into the issues FDA is currently examining for GenAI-enabled medical devices, including risk assessment, evidence generation, performance monitoring and management of modifications.
For developers and manufacturers, this creates an opportunity to provide practical and technical input at an early stage, before FDA has formulated proposed regulatory expectations or policy. Feedback may be particularly relevant where the approaches discussed raise feasibility, evidence or implementation challenges.
Who should consider responding?
Manufacturers and developers of GenAI-enabled medical devices
Medical device developers working with third-party foundation models
Healthcare organizations and professionals using or evaluating these technologies
Researchers and organizations with expertise in medical AI evaluation, benchmarking or monitoring
Professional societies and standards-setting organizations active in medical AI
Practical implications
Stakeholders should consider:
Reviewing whether FDA's discussion topics are relevant to current or planned GenAI-enabled devices
Identifying practical challenges with the risk assessment, benchmarking and clinical evaluation approaches discussed
Assessing implications for postmarket monitoring and management of model changes
Providing focused technical or operational evidence where it could inform FDA's early thinking
Support with stakeholder responses
We support organizations in:
Assessing whether discussion papers are relevant to their products, technologies, or business objectives
Identifying strategic risks, opportunities, and emerging regulatory trends
Preparing structured and evidence-based responses to authorities
Contact us if you would like to discuss how this request may affect your organization, software portfolio, or planned regulatory activities.
Note
Check back regularly for updates on ongoing consultations and emerging regulatory
trends.